Company: NDRA
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001654954-25-011797
Chunk: 8

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 7.01
Chunk 8
---
Item 7.01 Regulation FD Disclosure.

On October 13, 2025, the Company issued a press release announcing the Offering and estimated aggregate gross proceeds of up to approximately $14.4 million, taking into account potential proceeds from the exercise of the Common Warrants, to launch the Company’s DAT strategy. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01Other Events.